AVANIR Pharmaceuticals Announces FDA Approval Of NUEDEXTA™
Links shared publicly online about this topic.
- 764total visits
AVANIR Pharmaceuticals Announces FDA Approval Of NUEDEXTA™
View full resource at medicalnewstoday.com
Tags: Neurology, Drug, Pharma, FDA
Most Recently Shared on October 30, 2010 at 3:05 pm By:
AVANIR Pharmaceuticals Announces FDA Approval Of NUEDEXTA™ http://mnt.to/3LTB #pharma #pharmaceutical
Also Shared By:
AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription
news-medical.net — “AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).” View full resource at news-medical.net
Most Recently Shared on February 1, 2011 at 7:30 am By:
Parkinson's Disease: AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription: AVANIR Pharmaceuti... http://bit.ly/f8tsV5
Avanir Pharmaceuticals Announces FDA Approval of Nuedexta
drugs.com — “Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) is used to treat pseudobulbar affect. Includes Nuedexta side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 2, 2010 at 6:41 am By:
Avanir Pharmaceuticals Announces FDA Approval of Nuedexta - http://bit.ly/czapU6
Nuedexta approved for pseudobulbar affect - ONA
oncologynurseadvisor.com — “Avanir Pharmaceuticals announced that the FDA has approved Nuedexta (dextromethorphan hydrobromide and quinidine sulfate capsules) for the treatment of pseudobulbar affect (PBA).” View full resource at oncologynurseadvisor.com
Most Recently Shared on November 1, 2010 at 3:56 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Nuedexta approved for pseudobulbar affect http://goo.gl/fb/R1BMQ
Avanir Drug Nuedexta Wins FDA Approval for Uncontrolled Laughing, Crying - Bloomberg
bloomberg.com — “Avanir Pharmaceuticals Inc. won U.S. approval for a drug that curbs bouts of uncontrolled laughing or crying in patients with neurological disorders, regulators said. Shares more than doubled in extended trading.” View full resource at bloomberg.com
Most Recently Shared on October 30, 2010 at 2:09 am By:
Avanir Drug Nuedexta Wins FDA Approval for Uncontrolled Laughing, Crying http://bit.ly/bgUqYP
AVANIR Pharmaceuticals Announces Zenvia Review Timeline Established By FDA With PDUFA Date Of October 30, 2010
medicalnewstoday.com — “AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the Company's Complete Response to the October 2006 Approvable Le” View full resource at medicalnewstoday.com
Most Recently Shared on May 19, 2010 at 8:16 am By:
MNT Neurology News Neurology and Health News
AVANIR Pharmaceuticals Announces Zenvia Review Timeline Established By FDA With PDUFA Date Of October 30, 2010 http://mnt.to/3CMt #neurology
AVANIR Pharmaceuticals Submits Complete Response To FDA Approvable Letter For Zenvia In PBA
medicalnewstoday.com — “AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for” View full resource at medicalnewstoday.com
Most Recently Shared on May 5, 2010 at 1:26 am By:
MNT Drug Approvals Health News
AVANIR Pharmaceuticals Submits Complete Response To FDA Approvable Letter For Zenvia In PBA http://mnt.to/3C7P #regulatory
AVANIR Pharmaceuticals announces filing of Complete Response to FDA Approvable Letter for Zenvia
news-medical.net — “AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia" (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.” View full resource at news-medical.net
Most Recently Shared on May 3, 2010 at 8:38 am By:
AVANIR Pharmaceuticals announces filing of Complete Response to FDA Approvable Letter for Zenvia: AVANIR Pharmaceu... http://bit.ly/d0fdDE
Advertisement
MNT Drug Approvals
@mnt_drugapprov
AVANIR Pharmaceuticals Submits Complete Response To FDA Approvable Letter For Zenvia In PBA http://mnt.to/3C7P #regulatory
1 year ago...